Top Tweets for #ESPERION
1-1 Premier
1⃣ 5-13 #Esperion
2⃣ 13-6 #Orizon
GG's
Big thanks to @eMbyVAL for subbing in!
#SwimOrSink
Won Contenders DACH Playoffs 🥳🏆
W TEAM:
@bless1vlr
@kear7319
@wowolfvlr
@kAzaVLR
& COACHES:
@LoweVLR
@JayKayVLR
- 13 : 9 vs #Esperion
- 13 : 11 vs #HamburgUniFinal
Finals:
13 : 11 // 13 : 8 vs @FishInGlassVAL
Felt cheeky calling on the smokes today 😝
WON CONTENDER PLAYOFFS 🏆
Players:
@kAzaVLR
@kear7319
@wowolfvlr
@bless1vlr
Coaches:
@LoweVLR
@JayKayVLR
1st Game: 13 : 9 vs #Esperion
2nd Game: 13 : 11 vs #HamburgUni
Final Game: 13 : 11 and 13 : 8 vs @FishInGlassVAL
GGs to everyone well played and
FUCK THE HATERS
$ESPR New Guidelines Advertising #statin #Statinalternative #ldl #heart #health #statins #NEXLIZET #NEXLETOL #EZETIMIBE #PCSK9 $AMGN $MRK $PFE $JNJ
1:1 in todays week of contender dach so we are 3:3
decent week still a lot to improve
🟥8-13 #Esperion
🟩13-3 #Hallobaby
GGs to both teams
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session $ESPR, #EsperionTherapeutics, #EsperionTx, #Esperion https://t.co/7VlMC9gkTm
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia $ESPR, #EsperionTherapeutics, #EsperionTx, #Esperion https://t.co/ovHaaBhU7V
If you found this useful, follow me @_ShahKruti for weekly breakdowns of under-the-radar companies doing interesting things.
No hype. No noise. Just the business behind the business.
Retweet Tweet 1 if this opened your eyes to Esperion. ♻️
#Esperion #Pharma #biotech #investing #HealthcareStocks
12/12
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) & NEXLIZET (bempedoic acid & ezetimibe) Prior to April 19, 2040 $ESPR, #EsperionTherapeutics, #EsperionTx, #Esperion https://t.co/RIuERienFV
Exciting news from $ESPR! Esperion sets ambitious Vision 2040 to lead in cardiovascular prevention & beyond. 💼🚀 #Esperion #Cardiometabolic #GrowthStrategy
💡 Seen it? Spread it! Smash 🔁 & ❤️! https://t.co/GIxyDP3ao4
📉 Esperion $ESPR cae tras alcanzar los 3,50$, zona de fuerte resistencia técnica. Dilución a 2,50$ congela el rally. Como siempre la música se para de golpe, no avisan... o quizás sí....???
#Marketsbets #Esperion
$ESPR #H.C.Wainwright 27th #Esperion
What personally intrigued me and continues to occupy my thoughts are several points raised at the H.C. Wainwright 27th Conference:
1) The fact that Sheldon avoided answering the question: “And besides PSC, are there additional indications coming down the road?”
In my view, however, the answer can be found in the R&D Day held on April 24.
2) The reference to the ACLY platform and the statement: “But the science around ACLY biology is very interesting and leads to discovery of, you know, a lot of other targets” — Sheldon Koenig.
The establishment of an ACLY research platform, combined with the use of AI, is, in my opinion, a logical and forward-looking step for Esperion, which today is the clear leader in this field. As for the prospects of ACLY, it represents a future major drug class for combating a wide range of diseases. I believe that in 2027–2028, once cash flow significantly accelerates, the company will launch several large-scale studies.
3) “We're expecting to be very prominent in the guidelines” (AHA/ACC guideline update, Q1 2026) — Sheldon Koenig, H.C. Wainwright 27th.
This point in particular generates the most reflections and a strong desire to better understand the expectations regarding the AHA/ACC guideline updates scheduled for early 2026. However, I believe that much will become clearer during the AHA Scientific Sessions 2025, scheduled for November 7–10, 2025, in New Orleans.
That is all for now.
$ESPR #Esperion #Biotech #Forecasts
Q2 2025, Earnings Call – Question Session
Question from Dennis Ding, Jefferies:
“How do you view the consensus U.S. revenue for the year, which is around $170 million?”
Response from Ben Holliday, CFO:
“I think this was a good quarter in term of beating consensus and we’re tracking well ahead of where we would want to be for that.”
Outlook on U.S. Sales:
I project U.S. revenue to reach $201 million in 2025. For further details, please refer to my analysis here: https://t.co/ZzXiMhpcLg
Last Seen Hashtags on Sotwe
public dick flash
Seen from United States
yalovapasif
Seen from Turkey
国漫精品
Seen from Malaysia
telegram
Seen from Mexico
性斗
Seen from United States
submissivewoman
Seen from Germany
dykebreaking
Seen from Sweden
wataa
Seen from Turkey
momson()**+filter:native_video
Seen from Mexico
temptress
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
241.1M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.3M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.1M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.3M followers
KATY PERRY
@katyperry
88.6M followers
Taylor Swift
@taylorswift13
82.5M followers
Lady Gaga
@ladygaga
74M followers
Virat Kohli
@imvkohli
71.4M followers
Kim Kardashian
@kimkardashian
70.2M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.4M followers
Neymar Jr
@neymarjr
64.3M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.7M followers
X
@x
60.8M followers